Llwytho...

Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer

One of the major recent clinical advances in cancer treatment is the use of antiangiogenic drugs such as bevacizumab, sorafenib, and sunitinib. Bevacizumab, the monoclonal anti-VEGF antibody, has been approved for the first line treatment of metastatic breast cancer (MBC) when combined with taxane....

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Breast
Prif Awdur: Kerbel, Robert S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2009
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4540343/
https://ncbi.nlm.nih.gov/pubmed/19914541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0960-9776(09)70271-1
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!